CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
Abroad (travel likely)RecruitingPHASE1
Conditions
Leukemia, Myeloid, Acute
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Abramson Cancer Center Clinical Trials Service) · PMCancerResearch@pennmedicine.upenn.edu · 215-349-8245
Study leads
Noelle Frey, MD
Principal Investigator
University of Pennsylvania